Toward an Integrated Strategy for Volumetric Muscle Loss Regeneration

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Skeletal Muscle Biology

Background:

• Volumetric muscle loss (VML) causes persistent functional deficits from irreversible skeletal muscle loss, fibrosis, and inflammation.
• Current VML treatments like grafting have significant donor-site morbidity and limited functional integration.
• No FDA-approved regenerative therapies exist for VML, highlighting a critical translational gap.

Purpose of the Study:

• To synthesize skeletal muscle repair by integrating biological processes with advanced biomaterials and biofabrication technologies.
• To analyze how scaffold design parameters influence cellular responses and tissue integration for VML.
• To evaluate emerging regenerative strategies and regulatory considerations for VML therapies.

Main Methods:

• Systems-level synthesis of skeletal muscle repair mechanisms.
• Analysis of scaffold design parameters (alignment, porosity, stiffness, degradation, bioactivity).
• Evaluation of emerging strategies including 3D bioprinting, stem cell/exosome therapies, and bio-functional stimulation within a mechanobiological framework.

Main Results:

• Scaffold design critically influences cellular responses and tissue integration in VML repair.
• Emerging strategies like 3D bioprinting and cell-based therapies offer potential for VML regeneration.
• Regulatory pathways for VML therapies, often as combination products, require rigorous validation.

Conclusions:

• Integrating biological principles, engineering design, and regulatory insights is crucial for VML regenerative therapies.
• Key opportunities and challenges exist in advancing next-generation regenerative strategies for VML.
• Future priorities include rigorous preclinical validation and standardized manufacturing for clinical translation.